Smoking Cessation and Nicotine De-Addiction Market to Develop Rapidly by 2031, TMR Study

Smoking cessation therapy lowers the risk of cancer and other serious health issues. Smoking cessation and nicotine de-addiction products include OTC products (with nicotine), prescription products, and prescription products (without nicotine). These products are used to help users quit smoking. Rise in awareness about counseling, behavior therapy, medicines, and nicotine-containing products, such as nicotine patches, gum, lozenges, inhalers, and nasal sprays, is expected to drive the global smoking cessation and nicotine de-addiction market.

Rise in Number of People Quitting Smoking to Boost Global Market

According to the World Health Organization (WHO), tobacco kills more than 8 million people each year. More than 7 million of these deaths are the result of direct tobacco use, while around 1.2 million are the result of non-smokers being exposed to secondhand smoke. 80% of the world's 1.3 billion tobacco users reside in low- and middle-income countries where the burden of tobacco-related illness and death is the heaviest. In 2021, 65.3% of youth (middle and high school students) who used smoking cessation medication or products were seriously thinking about quitting the usage of all tobacco products.

Cigarette and tobacco addicts can be better treated with smoking cessation products. Smoking cessation medications and tobacco cessation tools comprise nicotine replacement therapy (NRT), electronic cigarettes, and therapeutic medication such as anti-depressants and nicotine receptor agonists that help in quitting smoking and preventing diseases caused due to smoking. Hence, rise in number of users who quit cigarettes due to the usage of quit-smoking products is a key factor driving the global smoking cessation and nicotine de-addiction market.

Get PDF sample for Industrial Insights and business Intelligence @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1849

Increase in Adoption of E-cigarettes to Propel Smoking Cessation and Nicotine De-Addiction Market

Rise in number of users preferring e-cigarettes is driving the smoking cessation and nicotine de-addiction market. E-cigarettes do not produce tar or carbon monoxide ? two of the most harmful elements in tobacco smoke. The liquid and vapor contain some harmful chemicals that can also be found in cigarette smoke; however, they are at much lower levels. The number of e-cigarette users increased from around 700,000 in 2012 to 3.6 million in 2019, falling to 3.2 million in 2020, and rising again to 3.6 million in 2021. Popularity of e-cigarettes is higher as they are safer than combustible cigarettes. E?cigarettes can also help smokers quit combustible cigarettes. Consequently, rise in popularity of e-cigarettes over cigarettes among young users is driving the smoking cessation and nicotine de-addiction market.

Growth in Demand for Nicotine Replacement Therapy (NRT) Products

According to the Foundation for a Smoke-Free World, based in the U.S., the total retail market for NRT and smoking cessation products stood at US$ 2.5 Bn in terms of value in 2020. NRT gum accounted for 51.4% share, while NRT lozenges held 21.3% share of the market in the same year. NRT patches accounted for 20.4% share, and NRT inhalers held 1.0% share. North America and Europe are the only regions that witnessed substantial sales for NRT products, accounting for 50.3% and 38.8% of total sales, respectively, in terms of value, in 2020.

NRT products include vaping products, heated tobacco, and tobacco-free oral nicotine. North America and Europe hold major share of the total demand for NRT products globally. Penetration of NRT products is low in countries in Asia Pacific compared to that in developed regions. Hence, Asia Pacific is likely to offer significant opportunities for key manufacturers of NRT products.

High Sales of Smoking Cessation and Nicotine De-Addiction Products through Offline Distribution Channel

In terms of distribution channel, the offline segment holds major value share of the global market. The online segment is estimated to grow at a notable CAGR during the forecast period. Users are preferring offline stores such as hospital pharmacies, local medical stores, and supermarkets due to the easy availability of a wide range of products. Users can also choose according to their preference.

key players.

Pfizer Inc., GlaxoSmithKline plc (GSK), Cipla Ltd., Johnson & Johnson (J&J), ITC Ltd., Takeda Pharmaceutical Company Ltd., Alkalon A/S, 22nd Century Group, Inc., Strides Pharma Science Ltd., and JUUL Labs, Inc are the key players operating in the global smoking cessation and nicotine de-addiction market.      

Get a Customized Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1849

Regional Outlook of Global Smoking Cessation and Nicotine De-Addiction Market

In terms of value, North America leads the global smoking cessation and nicotine de-addiction market, followed by Europe and Asia Pacific. The U.S. is the largest smoking cessation and nicotine de-addiction market in the world and accounts for a prominent share in terms of value and volume. High share of the U.S. can be ascribed to the significantly high usage of e-cigarettes among teenagers in the country. Usage of e-cigarettes among high school students in the U.S. increased from 1.5% in 2011 to 19.6% in 2020.

Europe is also a prominent market for smoking cessation and nicotine de-addiction products globally. The U.K. is the second-largest smoking cessation and nicotine de-addiction market in the world, after the U.S. It is the largest smoking cessation and nicotine de-addiction market in Europe. Nicotine-containing OTC smoking cessation products are the most preferred nicotine replacement therapy (NRT) products in the U.K. Rise in awareness about smoking cessation benefits among the people and increase in number of smoking cessation programs are driving the market in Europe.